Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 16/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612440 | 0.94 | TRPA1 (0.89) | TRPA1MAPTSMN1; SMN2LMNATRPV4 | |
| SCHEMBL612083 | 0.92 | TRPA1 (0.85) | TRPA1MAPTTRPV4 | |
| SCHEMBL10171767 | 0.90 | TRPA1 (0.81) | TRPA1MAPTSMN1; SMN2LMNA | |
| SCHEMBL612533 | 0.89 | TRPA1 (0.80) | TRPA1MAPTSMN1; SMN2LMNA | |
| SCHEMBL610604 | 0.88 | TRPA1 (0.79) | TRPA1MAPTTRPV4 | |
| SCHEMBL611633 | 0.85 | TRPA1 (0.73) | TRPA1MAPTSMN1; SMN2LMNA | |
| SCHEMBL608736 | 0.84 | TRPA1 (0.76) | TRPA1MAPTTRPV4 | |
| SCHEMBL612328 | 0.82 | TRPA1 (0.84) | TRPA1MAPTSMN1; SMN2TRPV4 | |
| SCHEMBL10171007 | 0.82 | TRPA1 (0.70) | TRPA1MAPT | |
| SCHEMBL610490 | 0.81 | TRPA1 (0.69) | TRPA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411393-B1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2014-01-22 | — | — | EP | claimed |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | claimed |
| US-20160158236-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20160158236-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-06-09 | — | — | US | disclosed |
| US-9186360-B2 | Treatment of respiratory disorders using TRPA1 antagonists | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-11-17 | — | — | US | disclosed |
| US-9186360-B2 | Treatment of respiratory disorders using TRPA1 antagonists | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-11-17 | — | — | US | disclosed |
| EP-2708538-B1 | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators | GLENMARK PHARMACEUTICALS SA (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-9000159-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-07 | — | — | US | disclosed |
| US-9000159-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-07 | — | — | US | disclosed |
| US-9000159-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-07 | — | — | US | disclosed |
| US-20140364445-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND AN ANTICHOLINERGIC AGENT | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-12-11 | — | — | US | disclosed |
| US-8623880-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-01-07 | — | — | US | disclosed |
| US-8623880-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-01-07 | — | — | US | disclosed |
| WO-2013014597-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID | GLENMARK PHARMACEUTICALS SA (CH) | 2013-01-31 | — | — | WO | disclosed |
| WO-2012176105-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A LEUKOTRIENE RECEPTOR ANTAGONIST | GLENMARK PHARMACEUTICALS SA (CH) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012176143-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A BETA-2 AGONIST | GLENMARK PHARMACEUTICALS SA (CH) | 2012-12-27 | — | — | WO | disclosed |
| US-20120316136-A1 | TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316136-A1 | TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364445-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND AN ANTICHOLINERGIC AGENT | TRPA1, TRPV1, TRPV5 | TRPA1 1/4885MAPT 404/4885SMN1; SMN2 930/4885 |
| US-20120316136-A1 | TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885MAPT 2700/4885SMN1; SMN2 1149/4885 |
| US-20160158236-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885MAPT 503/4885SMN1; SMN2 1572/4885 |
| US-20120041004-A1 | FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS | TRPA1, TRPV1, TRPC3 | TRPA1 1/4885MAPT 2007/4885SMN1; SMN2 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.